AVR anteristech.com Expected net earnings per share growth this year

Strict barriers for competitors due to biomimetic valves seem redundant while year-over-year EPS growth rates exhibit volatility. The value of 56.10 reflects the latest metric value, confirming the effectiveness of DurAVR in leading clinics. Anteris Technologies Global (AVR) bases its business stability on a deep scientific approach and the recruitment of top biomedical experts through a stock option system.

AVR (anteristech.com) Net earnings per share growth this year history from 12/14/2024 to 11/15/2026

Financial and market metric breakdowns for Anteris Technologies Ltd (AVR)

- current quotes and average value forecast:

Market Chart Anteris Technologies Ltd|AVR - Price Target Chart

- market capitalization data:

Market Capitalization Anteris|AVR - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Accounting Value of a Share Anteris Technologies Global|AVR - Company Net Assets|Market Cap to Book Value Multiple anteristech.com|AVR - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

AVR - Company Net Income|Expected Profit Anteris Technologies Global|AVR - Price to Earnings Ratio|Projected Price to Earnings Ratio Anteris|AVR - PEG Multiple|Enterprise Value to EBITDA Multiple Anteris Technologies Global|AVR - Operating profit EBITDA|Net earnings per share for the last four quarters Anteris Technologies Global|AVR - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months anteristech.com|AVR - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Anteris Technologies Global

- company sales and revenue statistics:

AVR - Company Sales|Company Future Revenue Anteris|AVR - P/S Multiple|Projected Price to Revenue Anteris Technologies|AVR - Sales Growth YoY (Last Twelve Months)

Fundamental valuation:anteristech.com (AVR)

For the long-term investor, the reliability of Anteris Technologies Global (AVR) is determined by R&D efficiency and the success of clinical trials. This metric measures the year-over-year dynamics of net earnings per share; therefore, the annual EPS variance in percentage terms allows for an assessment of the startup's financial stability in the absence of revenue and while seeking strategic distribution partners for its innovative valve.

Main competitors